They are correct in calling out Illumina's de-facto monopoly rents they are extracting on the market, but sadly I don't share their wildly optimistic view that we are eminent for technological disruption that will re-start the price plummeting of whole genome sequencing.

Nanopores are no where near the throughput and accuracy of Illumina's sequencing by synthesis tech, and if there is a pathway to challenge Illumina's position, it will be extremely complex, iterative and _long_.

Meanwhile Illumina is amassing a billion dollar war chest and is adding its own complex and iterative improvements to its platform (two-color detection, longer and longer reads, higher cluster density), maintaining its market lead.

As much as the analogy to microprocessor manufacturing and Moore's law is alluring, the messy stuff of biology and single molecule chemical manipulation and sensor detection is unlikely to obediently follow the same innovation curve.